1. Home
  2. PRSO vs TCRT Comparison

PRSO vs TCRT Comparison

Compare PRSO & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.96

Market Cap

9.8M

Sector

Technology

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$4.24

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
TCRT
Founded
2008
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.8M
8.1M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
PRSO
TCRT
Price
$0.96
$4.24
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
262.9K
65.9K
Earning Date
11-10-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,001,000.00
$6,000.00
Revenue This Year
N/A
$5,680,500.00
Revenue Next Year
$23.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.15
N/A
52 Week Low
$0.52
$1.31
52 Week High
$2.37
$6.20

Technical Indicators

Market Signals
Indicator
PRSO
TCRT
Relative Strength Index (RSI) 46.23 69.91
Support Level $0.97 $4.10
Resistance Level $1.15 $4.50
Average True Range (ATR) 0.08 0.35
MACD 0.03 0.08
Stochastic Oscillator 46.77 88.44

Price Performance

Historical Comparison
PRSO
TCRT

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: